Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE

Lancet Oncol. 2024 Nov;25(11):e602-e610. doi: 10.1016/S1470-2045(24)00262-6. Epub 2024 Aug 28.

Abstract

The European Society of Gynaecological Oncology, the European Society of Human Reproduction and Embryology, and the European Society for Gynaecological Endoscopy jointly developed clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing strategies and follow-up of patients with cervical cancers, ovarian cancers, and borderline ovarian tumours. The developmental process of these guidelines is based on a systematic literature review and critical appraisal involving an international multidisciplinary development group consisting of 25 experts from relevant disciplines (ie, gynaecological oncology, oncofertility, reproductive surgery, endoscopy, imaging, conservative surgery, medical oncology, and histopathology). Before publication, the guidelines were reviewed by 121 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover oncological aspects of fertility-sparing strategies during the initial management, optimisation of fertility results and infertility management, and the patient's desire for future pregnancy and beyond.

Publication types

  • Practice Guideline

MeSH terms

  • Female
  • Fertility
  • Fertility Preservation* / methods
  • Fertility Preservation* / standards
  • Humans
  • Infertility, Female / etiology
  • Infertility, Female / prevention & control
  • Ovarian Neoplasms* / pathology
  • Ovarian Neoplasms* / therapy
  • Systematic Reviews as Topic
  • Uterine Cervical Neoplasms* / pathology
  • Uterine Cervical Neoplasms* / therapy